Callan Capital LLC Increases Stake in Sanofi (NASDAQ:SNY)

Callan Capital LLC grew its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 81.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 23,434 shares of the company's stock after acquiring an additional 10,534 shares during the period. Callan Capital LLC's holdings in Sanofi were worth $1,300,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Golden State Wealth Management LLC increased its position in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares during the last quarter. Bessemer Group Inc. grew its position in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares during the last quarter. Lee Danner & Bass Inc. acquired a new stake in Sanofi during the fourth quarter worth about $31,000. UMB Bank n.a. grew its position in Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after buying an additional 264 shares in the last quarter. Finally, Wayfinding Financial LLC acquired a new stake in Sanofi during the first quarter worth about $63,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price for the company. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $61.50.

Sanofi Price Performance

NASDAQ:SNY traded up $0.33 during trading hours on Tuesday, hitting $48.65. The stock had a trading volume of 339,728 shares, compared to its average volume of 2,330,580. The company has a 50 day simple moving average of $50.52 and a two-hundred day simple moving average of $52.12. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. Sanofi has a one year low of $45.80 and a one year high of $60.12. The firm has a market capitalization of $119.30 billion, a price-to-earnings ratio of 17.37, a P/E/G ratio of 1.05 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The business's quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the company posted $1.78 EPS. Research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were paid a dividend of $2.0369 per share. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. This represents a dividend yield of 3.1%. Sanofi's payout ratio is presently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.